drugset / Trial / NCT00654407

Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia

NCT00654407

Phase 3 Completed 4875 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to atorvastatin and simvastatin alone.

Timeline

Start
2001-11
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 10 mg
Comparator Atorvastatin Small molecule 20 mg
Subject Rosuvastatin Small molecule 10 mg
Subject Rosuvastatin Small molecule 20 mg
Comparator Simvastatin Small molecule 20 mg
Comparator Simvastatin Small molecule 40 mg

Indications